Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense
17/04/2026 02:26
April 17 (Reuters) - Orthocell Ltd OCC.AX: FIRST SURGICAL USE OF REMPLIR IN US DEPARTMENT OF DEFENSE Further company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orthocell
See all newsBrief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense
Australia's Orthocell gains most in over a year on US approval for nerve repair device
Brief: Orthocell Ltd Receives Approval For Remplir In 51 Department of Defence Hospitals